Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. develops, manufactures and commercializes neuromodulation medical devices for cardiovascular disease. Its Barostim therapy is an implantable system that delivers electrical pulses to carotid baroreceptors to rebalance autonomic nervous system signaling and improve symptoms in heart failure patients.
Company updates commonly cover Barostim commercialization in the United States and Europe, FDA approval and Breakthrough Device history, CE Mark status for heart failure and resistant hypertension in the European Economic Area, clinical data from heart failure studies, reimbursement and coding developments, quarterly operating results, financing activity and board governance matters.
CVRx (NASDAQ: CVRX) announced that Humana issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. Humana covers about 5.2 million Medicare Advantage members across 46 states.
The policy applies to Barostim’s current FDA-approved indication and to patients in the BENEFIT-HF heart failure trial. CVRx calls this the first coverage policy for Barostim. It follows new Category I CPT codes and CMS Category B IDE coverage for BENEFIT-HF patients, both effective January 1, 2026.
CVRx (NASDAQ: CVRX) reported first quarter 2026 revenue of $14.8 million, up 20% year over year, driven by 22% U.S. growth to $13.7 million and 429 U.S. revenue units. Europe revenue was $1.1 million, down 2%.
Gross profit rose to $12.9 million with gross margin improving to 87%. Net loss was $13.1 million ($0.50 per share) versus $13.8 million a year ago. Cash and equivalents were $72.3 million, with $12.3 million used in operating and investing activities.
The BENEFIT-HF trial activated its first site, and the first patient was enrolled in Q2 2026. CVRx maintained 2026 revenue and opex guidance, while raising expected full-year gross margin to 85–87% and guiding Q2 2026 revenue to $15.1–$16.1 million.
CVRx (NASDAQ: CVRX) announced enrollment of the first patient in the BENEFIT-HF trial on May 4, 2026. The prospective, randomized, controlled study plans to enroll 2,500 patients at ~150 U.S. and Germany centers and is supported by CMS Category B IDE.
The trial will evaluate all-cause mortality and heart failure decompensation events through 2032 and, if successful, could expand the Barostim indicated population by about threefold.
CVRx (NASDAQ: CVRX) will release its first quarter 2026 financial and operating results after market close on Monday, May 11, 2026. The company will host a conference call at 4:30 p.m. ET the same day with a live webcast on its investor relations site.
Telephone dial-in numbers for the call are provided for U.S. and international callers; listeners are asked to dial in about ten minutes early.
CVRx (NASDAQ: CVRX) announced the nomination of Michael Dale to its Board of Directors; he will stand for election at the annual meeting on June 1, 2026. Mr. Dale is CEO and President of Axogen since August 2024 and previously led Abbott’s structural heart division for eight years.
The company emphasized Mr. Dale’s commercial and board experience as valuable for driving Barostim adoption within heart failure care.
CVRx (NASDAQ: CVRX) reported preliminary Q1 2026 results with revenue of $14.7–$14.8 million, about 20% growth versus Q1 2025. Gross margin is expected near 87%. Cash and cash equivalents were approximately $72.3 million as of March 31, 2026.
Reimbursement progress includes higher Medicare Advantage 30-day prior authorization approval rates (50% for Jan–Feb 2026). The first site in the BENEFIT-HF randomized trial was activated March 31, 2026, with enrollment expected to start in Q2 2026.
CVRx (NASDAQ: CVRX) announced scientific presentations and late-breaking clinical data on Barostim at THT 2026, March 2-4 in Boston. Key items include six-month outcomes from the REBALANCE Registry in over 400 patients, updates from BREATHE-HF, and initiation of the BENEFIT-HF trial.
The company will host a satellite program March 3, 12:15-1:30 p.m. ET, and said BENEFIT-HF has CMS Category B IDE coverage with enrollment expected to begin in the first half of 2026.
CVRx (NASDAQ: CVRX) reported Q4 2025 revenue of $16.0M (+4% YoY) and full-year 2025 revenue of $56.7M (+10% YoY). Gross margin rose to 85% (FY) and active U.S. implanting centers increased to 252.
The company initiated the BENEFIT-HF randomized trial (2,500 patients, CMS Category B IDE) and amended a term loan to an aggregate facility up to $100M, borrowing an additional $10M (outstanding principal $60M). 2026 revenue guidance: $63.0M–$67.0M.
CVRx (NASDAQ: CVRX) said it will release fourth quarter 2025 financial and operating results after market close on Thursday, February 12, 2026. The company will host a conference call to review results at 4:30 p.m. Eastern Time the same day and provide a live webcast on its investor relations site.
Telephone access is available for U.S. callers at 1-877-704-4453 and international callers at 1-201-389-0920; callers are asked to dial in about ten minutes early.
CVRx (NASDAQ: CVRX) announced initiation of BENEFIT-HF, a randomized trial planned to enroll 2,500 patients across ~150 U.S. and German centers to evaluate Barostim in a significantly expanded heart failure population. The primary endpoint is a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. BENEFIT-HF will test Barostim in patients with LVEF 50% (vs current indication 35%) and NT-proBNP 5,000 pg/mL (vs current 1,600 pg/mL), potentially expanding the indicated population roughly threefold. The trial has CMS Category B IDE coverage to support patient access during the study period.